MiMedx Group (NASDAQ:MDXG – Get Free Report) and Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, risk and dividends.
Insider and Institutional Ownership
79.2% of MiMedx Group shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 2.5% of MiMedx Group shares are held by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Analyst Ratings
This is a summary of current ratings and recommmendations for MiMedx Group and Protagonist Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MiMedx Group | 1 | 0 | 6 | 0 | 2.71 |
| Protagonist Therapeutics | 0 | 2 | 16 | 0 | 2.89 |
Valuation & Earnings
This table compares MiMedx Group and Protagonist Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MiMedx Group | $355.17 million | 1.97 | $48.58 million | $0.04 | 120.00 |
| Protagonist Therapeutics | $46.02 million | 203.73 | -$130.15 million | $1.03 | 140.67 |
MiMedx Group has higher revenue and earnings than Protagonist Therapeutics. MiMedx Group is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
MiMedx Group has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500.
Profitability
This table compares MiMedx Group and Protagonist Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MiMedx Group | 1.76% | 12.09% | 9.22% |
| Protagonist Therapeutics | 29.40% | 12.03% | 11.23% |
Summary
Protagonist Therapeutics beats MiMedx Group on 10 of the 14 factors compared between the two stocks.
About MiMedx Group
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins. The company’s patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company’s products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.
